TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03214718

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day
Description: For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry .
Study: NCT00652873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Tablets 0.5 mg (2 x 0.5 mg dose), fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dostinex
Description: Tablets, 0.5 mg (2 X 0.5 mg dose), fed
Study: NCT04009330

Intervention type: DIAGNOSTIC_TEST
Intervention: POC Assay
Description: Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS.
Study: NCT02136732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active self-management intervention
Description: Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control phone calls
Description: Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
Study: NCT03341273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be a matching capsule the same size, weight, and color as the capsules containing Azithromycin tablets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)
Description: The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
Study: NCT04416867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: 20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks
Study: NCT00944086

Intervention type: OTHER
Intervention: Recruitment Manoeuvre
Description: Recruitment Manoeuvre
Study: NCT00356135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel 10 mg
Description: 10 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel 10 mg
Description: 10 mg tablet taken orally
Study: NCT03341273

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)
Description: The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
Study: NCT01717014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidien Radial Reload Stapler with Tri-Staple Technology
Description: Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
Study: NCT01638936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT062 , intravenous administration
Description: Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
Study: NCT02281409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (KW-0761)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (KW-0761)
Study: NCT00374413

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial disk
Description: Implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial disk
Description: Implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial disc
Description: Implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial disc
Description: Implant
Study: NCT02275988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Study: NCT00356135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 75 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 75 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 75 mg tablet taken orally
Study: NCT02275988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study: NCT00356135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel placebo
Description: oral, as blinding mechanism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel placebo
Description: oral, as blinding mechanism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel 60 mg
Description: 60 mg (six 10-mg tablets) taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel placebo
Description: oral, as blinding mechanism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel placebo
Description: oral, as blinding mechanism
Study: NCT01834742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moviprep
Description: Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
Study: NCT03818737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Derived MSCs
Description: Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis. The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose-derived MSCs
Description: Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Tissue (UCT) MSCs
Description: Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
Study: NCT01834742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
Study: NCT02275546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring
Description: Drug-free placebo vaginal ring
Study: NCT03818737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
Study: NCT02275546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring
Description: Drug-free placebo vaginal ring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-use, non-sterile applicator
Description: Single-use, non-sterile, plastic applicator for insertion of vaginal ring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-use, non-sterile applicator
Description: Single-use, non-sterile, plastic applicator for insertion of vaginal ring.
Study: NCT04481269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface-modified composite coated orthopedic implants
Description: The surface-modified composite coated orthopedic implants have the capacity of high binding strength, high tissue-inducing activity and intelligent bacteria-resistance. The implant devices are expected to be used in the prevention and treatment of plant-related infections in orthopedic surgeries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional orthopedic implants
Description: conventional orthopedic implants
Study: NCT03421210

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine patch
Description: Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.
Study: NCT03423173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-003
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-003
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-003
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection
Study: NCT00570193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin (Visudyne)
Description: Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab (Lucentis)
Description: ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol
Study: NCT02831062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low protein diet + ketosteril
Description: Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
Study: NCT01388647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin
Description: During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
Study: NCT02115581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
Study: NCT00570141

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OASIS Wound Matrix
Description: OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
Study: NCT00770003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nasal spray solution. Once weekly intranasal administrations for one month.
Study: NCT04591366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barrier dressing
Description: A barrier dressing will be applied either pre or post implant prior to a culture swab and closing the incision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Barrier dressing
Description: A barrier dressing will be applied either pre or post implant prior to a culture swab and closing the incision.
Study: NCT03070002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02400320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Spray
Description: Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
Study: NCT03330704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Sodium Chloride
Description: 3% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23.4% Sodium Chloride
Description: 23.4% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.4% Sodium Bicarbonate
Description: 8.4% sodium bicarbonate will be infused into patients for the treatment or prevention of raised intracranial pressure
Study: NCT02673125

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MitoGrade
Description: MitoGrade refers to the mitochondrial DNA assessment in embryos.
Study: NCT04421287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhenyuan capsule
Description: 0.25g/ tablets, 2 tablets / TID, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zhenyuan capsule
Description: 0.25g/ tablets, 2 tablets / TID, for 12 weeks
Study: NCT03992924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: function or imaging guided PCI
Description: FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: function or imaging guided PCI
Description: FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology
Study: NCT02400320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Gel
Description: Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
Study: NCT03992924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: function or imaging guided PCI
Description: FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology
Study: NCT03462160

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control group
Description: Placebo will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal. The placebo appearance will be similar to the probiotic.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic experimental group
Description: Probiotic UroLact containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal.
Study: NCT01985841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumb
Description: Avastin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU
Study: NCT02400320

Intervention type: OTHER
Group type: OTHER
Intervention: Saline
Description: Saline
Study: NCT04014959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. Repetitive TMS (rTMS) is FDA-approved for depression treatment.~TMS is administered over 5 study visits: an initial TMS/fMRI session, a 3-day TMS intervention regimen, and a post-intervention TMS/fMRI session. During TMS/fMRI sessions, participants receive single pulses of TMS pre/post a short round of Intermittent Theta Burst Stimulation (iTBS), a modified rTMS protocol. Throughout the 3-day intervention regimen, participants receive two full rounds of iTBS daily.~All study participants receive active TMS.
Study: NCT01816152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Active intervention
Description: Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive intervention
Description: Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
Study: NCT04767490

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Duodenal Switch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Anastomosis Duodenal Switch
Study: NCT01890083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Study: NCT03433001

Intervention type: DRUG
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide capsules
Study: NCT01985841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Farmorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Endoxan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxotere
Study: NCT01905202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretrol
Study: NCT00172172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH/Calcium
Description: PTH(1-84) subcutaneous injection and calcium 700 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH/placebo
Description: PTH (1-84) injected subcutaneously and placebo provided orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo injected subcutaneously and 700 mg calcium orally
Study: NCT00351702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid with Ethambutol
Description: Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid with Ethambutol
Description: Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
Study: NCT01921712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PUR0200 Placebo
Description: Randomized, single dose of inhaled placebo matched to PUR0200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Randomized single dose of inhaled active comparator product
Study: NCT00713648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: 35 IU/kg body weight, i.v. administration, once every 4 weeks
Study: NCT02944136

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: enhanced usual care
Description: usual care from health providers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stepped collaborative care
Description: Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional